Walsh University is a private Roman Catholic university in North Canton, Ohio. It enrolls approximately 2,700 students and was founded in 1960 by the Brothers of Christian Instruction as a liberal arts college. Walsh College became Walsh University in 1993. The university offers more than 70 undergraduate majors and seven graduate programs, as well as multiple global learning experiences.
Background Over 20,000 medical malpractice lawsuits are filed annually, with plastic surgeons being particularly vulnerable. The evolving medico-legal landscape—shaped by tort reform measures, such as damage caps, medical review panels, and rising defensive medicine costs—demands ongoing evaluation. This study provides a comprehensive and up-to-date analysis of recent legislative changes in medical malpractice law and their implications for Plastic Surgery. Methods Medical malpractice laws across all 50 states were reviewed using the LexisNexis Academic Database. Key legal parameters assessed included the presence of medical review panels, caps on noneconomic, economic, and punitive damages, minimum malpractice insurance requirements, and statutes of limitations for malpractice claims. Results Fourteen states have implemented medical review panels. Economic damage caps exist in 6 states, ranging from $500,000 to $2,250,000 (average: $1,133,333). Noneconomic damage caps are present in 32 states, ranging from $350,000 and $2,250,000 (average: $516,414). While 3 states prohibit punitive damages entirely, 19 states impose no limits, and the remaining 28 enforce caps, often linked to other compensatory awards. Most states enforce a 2-year statute of limitations, although variations exist based on injury discovery rules. Conclusions Despite extensive research on tort reform and malpractice trends, the long-term effects of recent legislative changes remain uncertain. Variability in medico-legal policies across states may influence physician availability, underscoring the need for ongoing analysis and advocacy. Physicians must remain vigilant in high-risk specialties, while broader collaboration between the medical and legal communities is essential to fostering a legal framework that supports—rather than obstructs—high-quality patient care.
BACKGROUND:Nitrosylcobalamin (NO-Cbl), a vitamin B12-based nitric oxide donor, has demonstrated selective antitumor activity. However, its translational development has been limited by formulation challenges, including restricted solution concentration and concerns regarding stability. To address these limitations, we developed a nanoemulsion reformulation of NO-Cbl (NanoE-NO-Cbl). MATERIALS AND METHODS:NO-Cbl was reformulated into a nanoemulsion composed of soy lecithin, soybean oil, sucrose, and water using a high-shear Microfluidizer® processor. HPLC analysis and physicochemical characterization were used to assess NanoE-NO-Cbl for identity and stability across multiple storage conditions. Quantitative stability was evaluated by assay, chromatographic purity, pH, and droplet-size measurements. Antitumor activity was assessed in A375 melanoma cells using the sulforhodamine B (SRB) proliferation assay. RESULTS:Reformulation of NO-Cbl into a nanoemulsion increased the achievable formulation concentration relative to buffer-based preparations and enhanced potency approximately five-fold in A375 melanoma cells in vitro. NanoE-NO-Cbl demonstrated improved formulation stability under frozen and refrigerated storage conditions. CONCLUSION:Reformulation of NO-Cbl into a nanoemulsion improves formulation concentration, stability, and antitumor potency, providing a strong rationale for further preclinical development.
Biological signaling fundamentally relies on enzymatic integrity; however, chronic disease and aging induce irreversible enzymatic "uncoupling," creating fatal metabolic bottlenecks. While recent advances in materials science have focused on overcoming physical barriers to improve drug delivery [1], a critical challenge remains: the functional failure of endogenous machinery even after successful delivery. To address this, we report a Solid-state Signaling Transducer (SST) platform, the Boron-induced Amorphous Carbon Engine (B-ACE), designed to physically bypass dysfunctional enzymatic pathways. B-ACE utilizes a functional amorphous state termed "Active Disorder," which provides a high-density, three-dimensional interface for charge transfer. Unlike rigid crystalline structures, this configuration offers a stochastic network of junctions that facilitate quantum tunneling via p-type holes (h+), effectively replacing traditional enzymatic catalysis with a direct physical relay. Electrochemical analysis identified a potential-triggered transition peaking at 0.8 V, marking the activation threshold for hole-induced signaling. Crucially, the acidic gastric environment (pH 1.5 to 2.5) functions as a "protonic primer," effectively lowering this activation energy by approximately 0.35 V through Nernstian kinetics. This synergy enables the SST to fire autonomously within the physiological potential range, transforming the gastrointestinal tract into a physical ignition site for systemic signaling. The efficacy of this "physical bypass" was validated through multi-organ studies. B-ACE demonstrated a 46-fold enhancement in non-enzymatic NO generation in eNOS-/- models, effectively substituting for missing enzymatic functions. In spontaneously hypertensive rat (SHR) models, it achieved a superior vasorelaxation potency of pD2 approx. 7.95 with sustained signaling exceeding 18 hours. Furthermore, the platform restored neural and intestinal homeostasis by protecting dopaminergic neurons and suppressing inflammatory factors (NLRP3), showcasing its potential as a "universal recalibrator." This marks a paradigm shift from delivery-centric pharmacology to a bypass-centric bio-electronic intervention for systemic homeostatic recovery.
Power assist systems (PAS) on manual wheelchairs (MWC) aim to enable functional mobility and support the health of MWC users; however, current Medicare policy prohibits obtaining a PAS prior to one year of MWC use. Clinically, the authors have observed that when people needing a wheelchair have difficulty propelling at times in an MWC, they are likely to pursue a power wheelchair since PAS is not an option in the first year of use. Therefore, this scoping review aimed to explore the evidence related to PAS use through the lens of the International Classification of Functioning, Disability and Health framework. A total of 790 titles and abstracts were reviewed, with 26 articles included addressing mobility (n = 24), neuromuscular and movement (n = 10), cardiovascular and respiratory (n = 8), general tasks (n = 10), pain (n = 2) and mental functions (n = 2). Types of PAS represented included power assist push-rims (n = 23), rear-drive PAS (n = 4), and front-attached PAS (n = 1). Quantitative designs accounted for 23 studies, with 15 experimental designs. Overall, results positively supported the use of PAS across all environments, revealing reduced burden with propelling with proper training and support. The evidence did not support previous MWC experience as a factor in the user's ability to effectively use PAS.
BACKGROUND:Glioblastoma multiforme (GBM) remains a lethal brain tumor characterized by poor response to chemotherapy and limited blood-brain barrier (BBB) permeability. Nitrosylcobalamin (NO-Cbl), a nitric oxide (NO)-releasing cobalamin analog, was developed to selectively deliver cytotoxic NO to tumors through the transcobalamin II receptor (CD320). METHODS:NO-Cbl was evaluated across the NCI-60 tumor panel, followed by pharmacokinetic and biodistribution studies in glioblastoma-bearing rats using nitrate and cobalamin quantification in tissues, serum, and cerebrospinal fluid (CSF). Synergistic activity with TRAIL or temozolomide was assessed in human U87 and D54 glioma cells using SRB assays and Chou-Talalay analysis. RESULTS:NO-Cbl showed broad antitumor activity in vitro, with central nervous system tumor cell lines displaying intermediate sensitivity (mean ID50 = 17.6 μM). In vivo, NO-Cbl effectively crossed the BBB, with tumor nitrate levels peaking at 20.4 nmol/g at 30 min and remaining elevated at 24 h, confirming tumor-selective accumulation. Serum nitrate exhibited a rapid half-life (4-5 h), while serum and CSF B12 showed slower and variable clearance (21-26 h and 11-12 h, respectively). In glioma cell lines, NO-Cbl synergized with TRAIL and temozolomide (TMZ) (combination index < 1.0), enhancing antiproliferative effects and suggesting potential to overcome resistance mechanisms. CONCLUSION:This pilot study demonstrates that NO-Cbl crosses the BBB, accumulates selectively in brain tumor tissue, and synergizes with established and experimental glioblastoma therapies. These findings establish a translational foundation for developing cobalamin-based therapeutics as a novel treatment strategy for glioblastoma.
